Anti-Inflammatory Biologics Market Size to Record 5.9% CAGR Over 2023-2030; Growing Incidence of Inflammatory Disorders to Augment Market Progress

The anti-inflammatory biologics market size touched USD 93.13 billion in 2022 and is predicted to reach USD 93.32 billion in 2023. The market is anticipated to touch USD 139.80 billion by 2030, recording a CAGR of 5.9% over 2023-2030.

Fortune Business Insights™ presents this information in its latest report titled “Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030”.

Anti-inflammatory biologics is one of the most emerging treatments for treating autoimmune disorders. Inflammatory diseases, such as ulcerative colitis, psoriasis, inflammatory bowel diseases, and rheumatoid arthritis are growing at a worrying rate across the world, which is predicted to fuel the market growth.

COVID-19 Pandemic Accelerated Market Growth Due to Robust Sales of Biologics

The COVID-19 pandemic improved the market’s growth as several people, particularly those suffering from a severe case of COVID-19, suffered from acute inflammation. This scenario increased the need for repurposing anti-inflammatory medicines, which further boosted the market’s growth during this period.

Incyte Declared New Results from Clinical Trials Analyzing Its New Cream

Incyte declared new 104-week results from the important Phase 3 TRuE-V clinical trial program analyzing the effectiveness of its Opzelura (ruxolitinib) cream. The cream is utilized in patients falling in the age category of 12 years and above and suffering from nonsegmental vitiligo at the 2023 American Academy of Dermatology (AAD) Annual Meeting.

Growing Incidence of Inflammatory Disorders to Augment Market Progress

The prevalence of autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and ankylosing spondylitis is rising at a worrying rate, especially among the younger population. This factor has compelled market players to introduce novel anti-inflammatory biologics to treat these ailments and expand their customer base. These aspects are expected to support the market development.

However, many patients do not opt for biologics as the first line of treatment, which can restrict the market’s growth.

AbbVie Dominated Market Due to Strong Product Portfolio

AbbVie held a dominant position in the market as the company has a strong and vast product portfolio. Various factors, such as high investments in research & development, robust sales of Humira, and great market presence are helping the company dominate this market.

Notable Industry Development:

• April 2023: AbbVie announced that it had obtained the approval of RINVOQ from the European Commission (EC) as the first oral Janus Kinase (JAK) inhibitor to treat patients suffering from Crohn's disease.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/anti-inflammatory-biologics-market-102733

List of the Companies Profiled in the Report:

• AbbVie Inc. (U.S.)


• Merck & Co., Inc. (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Novartis AG (Switzerland)


• UCB S.A. (Belgium)


• Eli Lilly and Company (U.S.)


• Amgen Inc. (U.S.)


• Biogen (U.S.)

Further Report Findings

• North America held a dominant anti-inflammatory biologics market share in 2022 as there has been a notable rise in the demand for anti-TNF medicines across the region. Many leading market players are seeing a major growth in the number of potential pipeline candidates, which is further helping the regional market grow.


• Europe accounted for the second-largest share in the market in 2022 and is anticipated to register a significant CAGR during the forecast timeframe. Rising focus of market players on the launch of new anti-inflammatory biologics and substantial increase in research and development investments are some of the major factors fueling the market’s growth in the region.


• Based on drug class, the interleukin antagonist segment accounted for the largest market share in 2022 as these drugs are highly efficient in treating inflammatory diseases. Moreover, the demand for targeted therapies is rising among patients, which will further contribute to the segment’s growth.


• Based on application, the rheumatoid arthritis segment recorded a substantial revenue in 2022 due to the growing incidence of this disease and rising availability of more biologics for treating this ailment.

Table of Segmentation